Introduction:Phosphodiesterase 7 (PDE7) is a key enzyme in the PDE superfamily responsible for degrading cyclic adenosine monophosphate (cAMP) in pro-inflammatory and immunomodulatory cells. Elevated PDE7 activity is associated with inflammatory processes and various diseases. Suppression of PDE7 raises cAMP levels, reducing mucous secretion, cellular inflammation, and airway obstruction.Objective:This review provides an overview of the role of PDE7 in inflammatory disorders and highlights recent advances in the development of selective PDE7 inhibitors for therapeutic applications.Methods:The review consolidates findings on the structure-activity relationships of PDE7 inhibitors. Key structural classes of small molecule inhibitors, including quinazolinone derivatives, thiadiazines, pyrimidines, and others, are discussed alongside preclinical and clinical data on selective inhibitors such as BRL50481 and OMS527.Results:Selective PDE7 inhibitors have shown exposed potential in animal models to reduce cAMP degradation, leading to decreased inflammation and airway obstruction. BRL50481 remains the only commercially available selective PDE7 inhibitor, while OMS527 has progressed to clinical trials, demonstrating promise in treating inflammatory, neurological disorders, and leukemias.Conclusion:Selective PDE7 inhibitors represent a novel therapeutic class for inflammatory and neurodegenerative diseases. Further research is characterised by immune dysregulation.

2025-03-07·Organic Letters

Nucleophilic Substitution of Tertiary Sulfonamides: Construction of Sulfonate Esters

Article

作者: Lu, Guodan ; Wang, Congzhou ; Zhang, Tao ; Wang, Yong ; Du, Xiangshuai ; Wan, Xiaobing

Under the combined action of trichloroisocyanuric acid (TCCA) and triflic acid (TfOH), tertiary sulfonamides are efficiently activated, leading to the in situ generation of electrophilic sulfonamide salts. These electrophilic salts subsequently undergo nucleophilic substitution by alcohols, resulting in the formation of sulfonate esters under mild conditions. Other advantages of this method include the absence of transition-metal catalysts, broad substrate applicability, and high functional-group tolerance.

2024-10-01·International Journal of Neuropsychopharmacology

Upregulation of Phosphodiesterase 7A Contributes to Concurrent Pain and Depression via Inhibition of cAMP-PKA-CREB-BDNF Signaling and Neuroinflammation in the Hippocampus of Mice

Article

作者: Zhang, Han-ting ; Zong, Shu-hua ; Zhang, Fang-fang ; Chen, Yan-han ; Wu, Ming-xia ; Zhang, Feng ; Zhou, Yan-meng ; Yu, Hai-yang ; Wang, Wei ; Song, Yan ; Chen, Shi-cai ; Wang, Hao

AbstractBackgroundPhosphodiesterases (PDEs) are enzymes that catalyze the hydrolysis of cyclic adenosine monophosphate AMP (cAMP) and/or cyclic guanosine monophosphate (cGMP). PDE inhibitors can mitigate chronic pain and depression when these disorders occur individually; however, there is limited understanding of their role in concurrent chronic pain and depression. We aimed to evaluate the mechanisms of action of PDE using 2 mouse models of concurrent chronic pain and depression.MethodsC57BL/6J mice were subjected to partial sciatic nerve ligation (PSNL) to induce chronic neuropathic pain or injected with complete Freund’s adjuvant (CFA) to induce inflammatory pain, and both animals showed depression-like behavior. First, we determined the change in PDE expression in both animal models. Next, we determined the effect of PDE7 inhibitor BRL50481 or hippocampal PDE7A knockdown on PSNL- or CFA-induced chronic pain and depression-like behavior. We also investigated the role of cAMP-protein kinase A (PKA)-cAMP response element binding protein (CREB)-brain-derived neurotrophic factor (BDNF) signaling and neuroinflammation in the effect of PDE7A inhibition on PSNL- or CFA-induced chronic pain and depression-like behavior.ResultsThis induction of chronic pain and depression in the 2 animal models upregulated hippocampal PDE7A. Oral administration of PDE7 inhibitor, BRL50481, or hippocampal PDE7A knockdown significantly reduced mechanical hypersensitivity and depression-like behavior. Hippocampal PDE7 inhibition reversed PSNL- or CFA-induced downregulation of cAMP and BDNF and the phosphorylation of PKA, CREB, and p65. cAMP agonist forskolin reversed these changes and caused milder behavioral symptoms of pain and depression. BRL50481 reversed neuroinflammation in the hippocampus in PSNL mice.ConclusionsHippocampal PDE7A mediated concurrent chronic pain and depression in both mouse models by inhibiting cAMP-PKA-CREB-BDNF signaling. Inhibiting PDE7A or activating cAMP-PKA-CREB-BDNF signaling are potential strategies to treat concurrent chronic pain and depression.

100 项与 BRL-50481 相关的药物交易

登录后查看更多信息